In the early stage of development of TGFβ inhibitors as anticancer drugs, the focus was on targeted anticancer agent for suppressing the growth of cancer cells through the regulation of TGFβ signaling; however, such a possibility has been demonstrated at a nonclinical level only [1, 2]. This evidence concerns the gene TGFB1 and cancer.